LAUSR

Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease. There is a need for newer therapies to achieve disease control and reduce steroid related morbidity and mortality. Janus Kinase (JAK) inhibitors (Jakinibs) represent a new class of oral therapeutic, which targets cytokine receptor signaling thus blocking cytokine-induced gene transcription. In this review, we assess the current evidence of efficacy of Jakinibs for the various clinical forms of SLE. The key role of interferon signaling in SLE is well documented. JAK inhibition can normalize abnormal expression of interferon-related genes in SLE. Murine models have been used to demonstrate the efficacy of Jakinibs in preventing and ameliorating features or SLE including nephritis, skin inflammation, vascular dysfunction, and serological markers. Case reports and small series suggest that Jakinibs may be used to treat SLE and cutaneous lupus erythematosus (CLE). A recent clinical trial suggests that baricitinb may have therapeutic utility in SLE. Jakinibs may have particular efficacy for the management of CLE and cutaneous forms of monogenic lupus (chilblain lupus). Ongoing studies will clarify the utility of Jakinibs for the treatment of various manifestations of SLE.